Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 3/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 2/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17184011 | 1.00 | DRD2 (0.47) | DRD2POLBKMT2AKDM4EALDH1A1 | |
| SCHEMBL15757887 | 0.87 | DRD2 (0.60) | DRD2KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL15757888 | 0.87 | DRD2 (0.60) | DRD2KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL15758065 | 0.85 | DRD2 (0.43) | DRD2KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL15758063 | 0.85 | DRD2 (0.43) | DRD2KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL17184001 | 0.85 | DRD2 (0.43) | DRD2KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL23777899 | 0.84 | TUBB1 (0.43) | DRD2KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL15757538 | 0.84 | TUBB1 (0.43) | DRD2KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL17184004 | 0.84 | TUBB1 (0.43) | DRD2KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL2552196 | 0.84 | PTGS1 (0.51) | DRD2KMT2AKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874669-B2 | Neuroprotective agents for treatment of neurodegenerative diseases | WAYNE STATE UNIVERSITY (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190076426-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY | 2019-03-14 | — | — | US | disclosed |
| US-20190038622-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY | 2019-02-07 | — | — | US | disclosed |
| US-10125127-B2 | Neuroprotective agents for treatment of neurodegenerative diseases | WAYNE STATE UNIVERSITY (US) | 2018-11-13 | — | — | US | disclosed |
| US-20150299180-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY (US) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299180-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | RTN4, NR4A1, NR4A3 | DRD2 280/4885POLB 3364/4885KMT2A 1736/4885 |
| US-20190076426-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | SMN1; SMN2, PARK7, SNCA | DRD2 611/4885POLB 3419/4885KMT2A 2698/4885 |
| US-20190038622-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | SMN1; SMN2, PARK7, SNCA | DRD2 611/4885POLB 3419/4885KMT2A 2698/4885 |
| US-10125127-B2 | Neuroprotective agents for treatment of neurodegenerative diseases | RTN4, NR4A1, NR4A3 | DRD2 280/4885POLB 3364/4885KMT2A 1736/4885 |
| US-10874669-B2 | Neuroprotective agents for treatment of neurodegenerative diseases | SMN1; SMN2, PARK7, SNCA | DRD2 611/4885POLB 3419/4885KMT2A 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.